BIOPHARMA CREDIT PLC

Share Issue/Capital Change • Dec 30, 2025

National Storage Mechanism | Additional information

RNS Number : 1840N

BioPharma Credit PLC

30 December 2025

30 December 2025

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE COLLEGIUM PREPAYMENT

The Company notes the announcement released on 30 December 2025 by Collegium Pharmaceutical, Inc. ("Collegium") regarding the prepayment in full of the initial US$645.8 million senior secured term loan, of which the Company had an initial investment of US$290.4 million.  The Company announced the US$645.8 million senior secured loan to Collegium on 30 July 2024. The Company's proportion of the prepayment proceeds amounted to US$261.4 million of principal together with US$2.6 million of prepayment fees and US$5.3 million of accrued interest. 

Following the Collegium prepayment, the Company's cash balance is approximately US$405 million. 

Pedro Gonzalez de Cosio of Pharmakon Advisors, LP, the investment manager of the Company, commented:

"We are grateful for Collegium's partnership and proud to have served as a trusted financing source over the past six years. While this early repayment will result in a higher-than-usual cash balance, we are encouraged by the strength of the broader pipeline and look forward to further diversifying the portfolio."

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

[email protected]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRFDSFDSEISEDE